Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Leghorn

40 clinical trials in Leghorn, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Leghorn at a glance
40
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

40 trials in Leghorn

Open in trial search

Non-small cell lung cancer+1

Recruiting

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Graves' disease

Recruiting

Long-Term Study of Imeroprubart in Adults With Graves' Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Graves' disease

Recruiting

Study of IMVT-1402 Treatment for Adults with Graves' Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imeroprubart
  • Sponsor:Immunovant Sciences GmbH

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Triple negative breast cancer

Recruiting

Study of sacituzumab tirumotecan, pembrolizumab and chemotherapy combination for early-stage triple-negative breast cancer or hormone receptor-low positive/HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal cancer

Recruiting

Study comparing cetuximab with chemotherapy versus bevacizumab with chemotherapy in patients with advanced colorectal cancer who have wild-type RAS and right-sided tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondazione GONO G.I.

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant and Everolimus for Patients with Advanced ER+/HER2- Breast Cancer Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Elacestrant
  • Sponsor:Medica Scientia Innovation Research S.L.

Colorectal cancer metastatic

Recruiting

Study of Atezolizumab with Drug Combination for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione GONO G.I.

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centro Di Riferimento Oncologico Di Aviano

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Leghorn

What the registry says about research in the country

01 Breast Cancer Research

Extensive investigations into HER2-positive and hormone receptor-positive breast cancer treatments. Studies focus on novel therapeutic combinations and targeted approaches for different stages of breast cancer.

  • Advanced metastatic treatments
  • Early-stage interventions
  • Hormone receptor therapies

Multiple trials evaluating innovative drug combinations and immunotherapy approaches for better patient outcomes.

02 Lung Cancer Studies

Research centered on non-small cell lung cancer (NSCLC) treatments, investigating immunotherapy combinations and targeted therapies for various stages of the disease.

  • Immunotherapy combinations
  • Resectable NSCLC treatments
  • ALK-positive targeted therapies

Focus on improving survival rates through innovative treatment approaches and combinations.

03 Colorectal Cancer Trials

Investigations into advanced colorectal cancer treatments, including studies on specific mutations and combination therapies for metastatic disease.

  • BRAF-mutant treatments
  • Immunotherapy approaches
  • Metastatic disease management

Emphasis on personalized treatment strategies based on specific genetic markers and disease characteristics.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.